From Microdosing to Mystical Experiences with Julianne Keu
Similar Posts
The Spotlight Round Up Video, March 17th
As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!
Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..
So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Discussing Extraction and the Colorado Gray Market with Nick Gay
In this episode, Dennis Walker sits down with Nick Gay, the Head of Product Development at Ousia Labs, to talk about what extraction is and why it has become a focus of many entrepreneurs in the psychedelic space, as well as discussing the massive gray market that is developing in Colorado.
Why I’m More Excited About MindMed’s 18-MC than its LSD treatments
Happy Holidays guys! I 🎄🙃 In this episode we’ll cover the many reasons why I’m more excited about MindMed’s 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed’s plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
#mindmedstock
![MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-88-600x338.jpeg)
MindMed Patents 18MC? A new Psychedelic ETF? [ Plus more MMED/MMEDF, LOBE, CYBIN & COOL Updates]
In today’s episode of “This Week in Psychedelic Stocks”, we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) , Core One Labs ( COOL) & Lobe Sciences (LOBE).
I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn’t the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing…
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00​ – Intro
1:18​ – New Psychedelic ETF (PSIL)
5:44​ – Baltimore decriminalizes the possession of all drugs
6:53​ – Hawaii to study the benefits of psilocybin
8:29​ – Harvard University to study psychedelics
9:42​ – UCSF also decides to study psychedelics
11:24​ – MindMed (MMED / MMEDF / MMQ) announced the company’s 2020 End-Year Financial results + link 12:32​ on video end year
12:50​ – MindMed files F10 File with the SEC ( important step before uplisting to the NASDAQ)
14:11​ – MindMed’s 2020 conference call highlights
15:06​ – MindMed (MMED) has now filed a patent application for its 18-MC compound
17:04​ – Cybin (CYBN / CLXPF) management restructuring
19:40​ – Core One Labs (COOL ) stock updates
20:48 – Lobe Sciences ( Lobe) company updates
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa…
​
https://benzinga.grsm.io/thepsychedel…
​
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed​​​ ​#MMED​​​ #MindMedStock​
Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), atai Life Sciences (atai: NASDAQ), Field Trip (FTRP: TSE) ( FTRP: NASDAQ), Cybin (CYBN: NYSE) and many more have experienced a decline in stock prices. So in this episode, we’ll be discussing the reasons behind this and whether we are ignoring some red flags.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #FieldTrip #PsychedelicStocks